Background: The aim of the study was to evaluate the radiation sensitizing ability of ERK1/2, PI3K-AKT and JNK inhibitors in highly radiation resistant and metastatic B16F10 cells which carry wild-type Ras and Braf.
Introduction
Ionizing radiation is a potent DNA damaging agent that interacts with cellular DNA and induces lesions in the irradiated cells and prevents cell proliferation and induces cell death by apoptosis or necrosis depending on the radiation dose. Due to its cell killing effect, radiation therapy is widely used as a primary source of treatment for numerous types of cancers. Tumor control could be best achieved with radiation therapy if the tumor is well localized. With the advancement in radiation treatment modalities, by precise physical and biological targeting, cancer could be more effectively treated with radiation therapy with minimal normal tissue damaging [1] . However, the major setback to use radiation therapy for several types of cancer is the development of radiation resistance.
Studies have shown that exposure of tumor cells to therapeutic doses of radiation activates cell survival signaling pathways such as EGFR-RAS [2] [3] [4] [5] and its downstream molecules such as ERK1/2, PI3K-AKT, JNK, etc. apart from several other signaling molecules [4, 6, 7] . Among these, ERK1/2 and AKT pathways are well known for their pro-survival and pro-proliferative activities, whereas JNK is a stress responsive pathway. Activation of these pathways further leads to the activation of multiple transcription factors, pro-and antiapoptotic proteins, cell cycle check point proteins, etc. [4, 6, 8] . Ionizing radiation has been shown to activate these signaling pathways in different intensities and in a cell type-dependent manner [6] . Activation of ERK1/2 triggers G2 checkpoint which is considered protective from radiation-induced cell death [8, 9] , while activated AKT is known to promote DNA repair and inhibition of apoptosis induction [10] . Thus apart from direct cytotoxic effect, the exposure of cancer cells to therapeutic doses of radiation also enhances the survival and proliferation of a fraction of cells which ultimately leads to radiation resistance and therapeutic inefficacy.
Generally it is arguable that inhibition of these pro-survival and pro-proliferative pathways activated due to radiation exposure has the great potential to improve the radiation sensitization of cancer cells. Since activation of these pathways is also dependent on the mutational status of Ras or Inhibition of ERK1/2 or AKT Activity World J Oncol. 2018;9(1): [21] [22] [23] [24] [25] [26] [27] [28] Braf [2, 11] , inhibition of epidermal growth factor receptor or its individual downstream pathways such as ERK1/2 or AKT signaling has been evaluated for their radio-sensitizing potential and found effective in certain cases both in vitro as well as in vivo studies with Ras or Braf mutations [12] [13] [14] [15] [16] [17] [18] . Radiation sensitization studies with cancer cells bearing wildtype Ras and Braf are very limited [19] . In the present study, using a highly radiation resistant and metastatic B16F10 cells which carry wild-type Ras and Braf [20] [21] [22] [23] [24] , it was shown that phosphorylated ERK1/2, AKT as well as JNK levels were significantly increased upon radiation exposure. Targeted inhibition of ERK1/2 and AKT pathways moderately but equally enhanced radiation-induced cell death while inhibition of JNK enhanced radiation-induced cell death to a lesser extent. However, combined inhibition of both ERK1/2 and AKT did not increase additional cell death, indicating that the radiation-induced cell death in B16F10 cells is possibly mediated by common downstream effector molecules of ERK1/2 and AKT.
Materials and Methods

Cell culture and treatment conditions
Mouse melanoma cell line B16F10 was procured from National Centre for Cell Science, Pune, India as well as from Department of Radiation Biology and Toxicology, School of Life Sciences, Manipal, India. Cells were cultured in DMEM media supplemented with 2 mM L-glutamine, 10% fetal bovine serum and 1 µg/mL of penicillin and streptomycin and maintained at 37 °C in a humidified incubator of 5% CO 2 . ERK1/2 activity was inhibited using U0126, PI3K-AKT kinase activity was inhibited using LY294002 and JNK activity was inhibited using SP600125 (all were from Calbiochem, USA). All the inhibitors were dissolved in dimethyl sulfoxide, aliquoted for single use and stored at -20 °C.
Radiation treatment
Cells (5 × 10 4 ) were seeded in 12.5 cm 2 culture flask and incubated for 24 h to allow for cell attachment and recovery. Media was aspirated and replaced with media containing the desired concentration of drug. After 24 h of incubation, cells in the flask were treated with 1.0, 2.0 and 3.0 Gy electron beam radiation (Microtron Centre, Mangalore University, India). After irradiation, cells were further incubated with drugs for either 4 or 24 h depending on the experimental requirement. To mimic the radiation treatment procedure, a batch of cultured cells were carried to radiation room in a similar way to radiation treatment groups but were not exposed to radiation. These sham-irradiated cells were used for comparing the actual effects of treatment along with control B16F10 cells.
Estimation of phosphorylated ERK1/2, AKT and JNK
Cells (1 × 10 5 ) were seeded in 12.5 cm 2 culture flasks and al- 
Evaluation of cell death
Cells (1 × 10 5 ) were seeded in 12.5 cm 2 culture flasks and allowed for cell attachment and recovery. After 24 h of incubation, media was aspirated and replaced with media containing 20 µM concentrations of U0126, LY294002 or SP600125.
After 24 h, cells were irradiated as explained earlier. After 24 h of irradiation, amount of cell death in different groups was measured using TUNEL assay (EMD Millipore, Cat.
No.4500-0121). Briefly, cells were detached from the flasks and washed twice with PBS and fixed in 1% paraformaldehyde in PBS on ice for 1 h, suspended in ice-cold ethanol (70%) and stored overnight at -20 °C. Cells were then washed twice in wash buffer and suspended in DNA labeling mix containing TdT enzyme and Brd-UTP. Samples were incubated in a humidified atmosphere for 1 h at 37 °C in the dark, washed in rinsing buffer, suspended in anti-BrdU staining mix containing anti-BrdU-TRITC and incubated for 30 min at room temperature in the dark. At the end of incubation, final volume was adjusted to 200 µL with rinsing buffer and quantified using the flow cytometry system (Guava EasyCyte, EMD Millipore) according to the manufacturers' instructions. The data were analyzed using the EasyCyte software module (EMD Millipore).
Statistical analysis
Data are presented as the mean ± SE from three independent experiments. Statistical analyses were performed by one-way ANOVA. P < 0.05 was considered to indicate a statistically Inhibition
Results
Exposure of B16F10 cells to radiation increased p-ERK1/2, p-AKT and p-JNK levels
Control B16F10 tumor cells, sham-irradiated cells and cells exposed to 1.0, 2.0 and 3.0 Gy of radiation were used to measure p-ERK1/2, p-AKT as well as p-JNK levels. No significant differences in any of the measured phosphorylated proteins were observed between control and sham-treated groups. However, exposure of B16F10 cells to 1.0, 2.0 and 3.0 Gy of electron beam irradiation triggered an increase in all the three phosphorylated proteins compared to sham-treated and control groups (Fig. 1) . Phosphorylated ERK1/2 and p-AKT were increased in a dose-dependent manner upon exposure to 1.0, 2.0 and 3.0 Gy of radiation at 4 h of post-irradiation (P < 0.01 to 0.0001). Increase in p-JNK levels were also significant upon exposure to 1.0, 2.0 and 3.0 Gy of radiation compared to control and sham-irradiated groups, although the increase was dose-independent.
Inhibition of ERK1/2 and AKT equally enhanced radiosensitivity of B16F10 cells exposed to 2.0 and 3.0 Gy electron beam radiation
In the first set of experiments, B16F10 cells were treated with 20 µM concentrations of U0126, LY294002 and SP600125, 24 h before exposing cells to 2.0 Gy of radiation. Treatment with 20 µM concentration of either U0126, LY294002 or SP600125 alone did not show significant increase in cell death at 48 h after drug treatment compared to control and sham group (data not shown). Treatment of B16F10 cells with 2.0 Gy of radiation produced significant amount of cell death compared to control groups (P < 0.0001, Fig. 2 ). B16F10 cells pre-treated with 20 µM U0126 showed further increase in cell death compared to 2.0 Gy radiation alone group (P < 0.001, Figs.  2 and 3) . Interestingly, B16F10 cells pre-treated with 20 µM LY294002 also yielded similar results comparable to treatment with U0126 (Figs. 2 and 3) . The enhancement in cell death induced by both U0126 and LY294002 was about 43% higher compared to 2.0 Gy radiation alone (Fig. 4) . However, cells It was interesting to find that whether the equal increase in cell death in the presence of either U0126 or LY294002 is an arbitrary finding or has more significance. For this, in the next set of experiments, B16F10 cells were treated with either 20 µM U0126 or 20 µM LY294002, 24 h before exposing cells to 3.0 Gy of radiation. With 3.0 Gy, radiation alone treatment produced significant amount of cell death compared to control as well 2.0 Gy of radiation exposure (Fig. 2) . Surprisingly, B16F10 cells pre-treated with either 20 µM U0126 or LY294002 prior to 3.0 Gy of radiation exposure showed almost equal increase in cell death (about 55%, Fig. 4 ) compared to 3.0 Gy group (Figs. 2 and 5 ). B16F10 cells pre-treated with 20 µM SP600125 prior to 3.0 Gy of radiation exposure also increased cell death compared to 3.0 Gy group (P < 0.01, Figs.  2 and 5) . However, the total increase in cell death is low compared to enhancement in radiation-induced cell death induced by U0126 and LY294002. Above two sets of experiments indicate that inhibition of either ERK1/2 or AKT activation prior to 2.0 or 3.0 Gy of radiation moderately but equally sensitized B16F10 cells to radiation-induced cell death while inhibition of JNK enhanced radiation-induced cell death at relatively low level.
Combined inhibition of ERK1/2 and AKT did not increase cell death compared to individual inhibition
From the above experiments, it is clear that inhibition of either ERK1/2 or AKT activity equally increases radiation-induced cell death. There is a possibility that combined inhibition of ERK1/2 and AKT activity could further enhance the radiationinduced cell death. To study this, B16F10 cells were treated with a combination of 20 µM each of U0126 and LY294002, 24 h before exposing cells to 2.0 Gy and 3.0 Gy radiation doses. Exposure of B16F10 cells treated with 20 µM U0126 and LY294002 to 2.0 Gy radiation resulted in significantly higher cell death compared to 2.0 Gy radiation alone treatment (Fig. 3) . However, the amount of cell death is not significantly higher compared to the cell death induced by individual ERK1/2 or AKT inhibition (Fig. 4) . Further, the similar trend was observed even at 3.0 Gy where, combined effect of ERK1/2 and AKT inhibition was not better than individual inhibition of either ERK1/2 or AKT (Figs. 4 and 5) . This suggests that ERK1/2 and AKT possibly protect survival against radiation-induced cell death through common downstream molecule/s in B16F10 cells.
Discussion
Exposure of tumor cells to clinically relevant low doses of ionizing radiation causes DNA damage and the generation of reactive oxygen species (ROS). The generated ROS plays an important role in the biological effects induced by ionizing radiation. It is believed that ROS generation subsequently leads to rapid activation of EGFR-Ras pathway and its downstream molecules such as ERK1/2, AKT, etc. [4, [25] [26] [27] [28] [29] [30] . Activated ERK1/2 and AKT pathways are well known to cause radiation resistance in Ras/Braf mutated tumor cells [2, 12-14, 16, 18] . The present study utilized a highly metastatic and radioresistant [21, 23] B16F10 cells that carry wild-type Ras or Braf [20, 22, 24] . Exposure of B16F10 cells to 1.0 to 3.0 Gy of radiation significantly increased p-ERK1/2, p-AKT as well as p-JNK levels. Although B16F10 cells are without mutations in Braf, Kras or Nras, it is highly possible that mutations in Pdgfra (well known to activate ERK1/2) as well as Atm (well known to activate PI3K-AKT) are responsible for the constitutive expression of ERK1/2 and AKT in B16F10 cells [24] , upon radiation exposure. Further, ERK1/2 is known to get activated by autocrine factors without mutations in Ras [31] . Activated ERK1/2 modulates the functions of several transcription factors, protein kinases, protein phosphatases, cytoskeletal proteins, signaling molecules, apoptosis-related proteins, as well as other types of proteins [32] , while activated AKT modulates the function of numerous substrates involved in the regulation of cell survival, cell cycle progression and cellular growth [33, 34] , whereas JNK acts as pro-apoptotic as well as anti-apoptotic depending on the conditions [35] . Interestingly, in B16F10 cells, it was observed that both ERK1/2 and AKT inhibition equally enhanced radiation-induced cell death, while inhibition of JNK did show radiation sensitization to a lesser amount. Further, the study showed that dual inhibition of ERK1/2 and AKT pathways failed to further increase Inhibition of ERK1/2 or AKT Activity World J Oncol. 2018;9(1): [21] [22] [23] [24] [25] [26] [27] [28] cell death compared to inhibition of ERK1/2 or AKT pathways individually. Thus, it is assumed that ERK1/2 and AKT possibly provide protection against radiation-induced cell death through common downstream molecule/s. Studies have shown that individually both ERK1/2 and AKT pathways activate multiple substrates leading to a wide range of effects on the cell [32, 36] . Additionally, ERK1/2 and AKT are known to cross talk with multiple substrates including several kinases, transcription factors, etc. which increase the complexity of the signaling network. For example, previous studies have shown that eukaryotic translation initiation factor (eIF4E) and cyclic AMP responsive element B (CREB) are known to be activated by radiation [37] [38] [39] [40] . Further both molecules are known to be activated by ERK1/2 and AKT [41] [42] [43] [44] . Several such molecules are expected to be cross talking in the network. It is required to evaluate them thoroughly in future studies. Overall the current study showed that even without activating mutations in Ras or Braf genes, ERK1/2 and AKT play a critical role in B16F10 cell survival upon radiation exposure and possibly act through common downstream effector/s.
